The rapid adoption of GLP-1 receptor agonists is driving unprecedented cost inflation within corporate self-insured health plans. Employers are balancing the long-term metabolic health benefits of coverage against immediate fiscal pressures on human resources budgets.
Utilization Management Programs Implemented
To control spend, corporate benefits directors are instituting step-therapy protocols, mandatory lifestyle intervention participation, and strict clinical thresholds prior to approving prescription coverage. Plan administrators report these measures have slowed expenditure growth while preserving access for high-risk cohorts.
Long-Term Claims Reduction Projections
Actuarial analyses suggest that high initial drug expenditures may be offset over multi-year horizons through reduced hospitalizations related to cardiovascular disease and type 2 diabetes, prompting calls for long-term health outcome tracking.